173 related articles for article (PubMed ID: 31328962)
1. Circulating endothelial and progenitor cells in age-related macular degeneration.
Mucciolo DP; Marcucci R; Sodi A; Cesari F; Murro V; Rogolino A; Rizzo S; Giusti B; Virgili G; Prisco D; Gori AM
Eur J Ophthalmol; 2020 Sep; 30(5):956-965. PubMed ID: 31328962
[TBL] [Abstract][Full Text] [Related]
2. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
3. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ
Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524
[TBL] [Abstract][Full Text] [Related]
4. Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration.
Abdolrahimzadeh S; Gharbiya M; Formisano M; Bertini F; Cerini A; Pacella E
Curr Eye Res; 2019 Sep; 44(9):1000-1005. PubMed ID: 30999772
[No Abstract] [Full Text] [Related]
5. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
[TBL] [Abstract][Full Text] [Related]
6. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
Inan S; Baysal Z; Inan UU
Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
[No Abstract] [Full Text] [Related]
8. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
Monés J; Biarnés M;
Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
[TBL] [Abstract][Full Text] [Related]
9. Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial.
Bailey C; Scott LJ; Rogers CA; Reeves BC; Hamill B; Peto T; Chakravarthy U; Harding SP;
Ophthalmology; 2019 Jan; 126(1):75-86. PubMed ID: 30301555
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity.
Chang YS; Han JI; Yoo SJ; Lew YJ; Kim JH
Korean J Ophthalmol; 2014 Dec; 28(6):466-72. PubMed ID: 25435749
[TBL] [Abstract][Full Text] [Related]
11. Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age-related macular degeneration patients.
Mottet B; Aptel F; Geiser MH; Hera R; Zhou T; Almanjoumi A; Vinh V; Chiquet C
Acta Ophthalmol; 2018 Nov; 96(7):e783-e788. PubMed ID: 30203609
[TBL] [Abstract][Full Text] [Related]
12. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
Lee JY; Chung H; Kim HC
Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
[TBL] [Abstract][Full Text] [Related]
13. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
14. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
15. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
16. EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.
Rahimy E; Ying GS; Pan W; Hsu J
Retina; 2019 Apr; 39(4):636-647. PubMed ID: 29517580
[TBL] [Abstract][Full Text] [Related]
17. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
18. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
Grierson R; Meyer-Rüsenberg B; Kunst F; Berna MJ; Richard G; Thill M
J Ocul Pharmacol Ther; 2013; 29(6):530-8. PubMed ID: 23573802
[TBL] [Abstract][Full Text] [Related]
19. Responses of Types 1 and 2 Neovascularization in Age-Related Macular Degeneration to Anti-Vascular Endothelial Growth Factor Treatment: Optical Coherence Tomography Angiography Analysis.
Kim JM; Cho HJ; Kim Y; Jung SH; Lee DW; Kim JW
Semin Ophthalmol; 2019; 34(3):168-176. PubMed ID: 31132283
[No Abstract] [Full Text] [Related]
20. PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Abdelfattah NS; Zhang H; Boyer DS; Sadda SR
Retina; 2016 Oct; 36(10):1843-50. PubMed ID: 27135213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
